Free Trial
→ Inside the Options Play With a High Historical Win Rate (From TradeWins) (Ad)tc pixel Free AVIR Stock Alerts

Atea Pharmaceuticals (AVIR) Financials

Atea Pharmaceuticals logo
$5.15 -0.01 (-0.19%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$5.14 -0.01 (-0.10%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Atea Pharmaceuticals

Annual Income Statements for Atea Pharmaceuticals

This table shows Atea Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -9.06 -14 -11 121 -116 -136 -168 -158
Consolidated Net Income / (Loss)		 -9.06 -14 -11 121 -116 -136 -168 -158
Net Income / (Loss) Continuing Operations		 -9.06 -14 -11 121 -116 -136 -168 -158
Total Pre-Tax Income 		-9.06 -14 -11 139 -119 -135 -167 -165
Total Operating Income		 -9.48 -15 -11 138 -131 -164 -193 -181
Total Gross Profit		 0.00 0.00 49 351 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 49 351 0.00 0.00 0.00 0.00
Operating Revenue		 0.00 0.00 49 351 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 9.48 15 60 213 131 164 193 181
Selling, General & Admin Expense		 2.80 4.44 22 46 49 50 49 33
Research & Development Expense		 6.68 10 38 167 82 114 144 148
Total Other Income / (Expense), net		 0.41 0.57 0.08 0.21 11 29 25 16
Interest & Investment Income		 0.41 0.57 0.08 0.21 11 29 25 16
Income Tax Expense		 - 0.00 0.00 17 -3.59 1.02 0.93 -6.16
Basic Earnings per Share		 ($0.90) ($1.39) ($0.51) $1.46 ($1.39) ($1.63) ($2.00) ($1.94)
Weighted Average Basic Shares Outstanding		 10.04M 10.09M 21.59M 82.82M 83.25M 83.39M 84.26M 81.50M
Diluted Earnings per Share		 ($0.90) ($1.39) ($0.51) $1.37 ($1.39) ($1.63) ($2.00) ($1.94)
Weighted Average Diluted Shares Outstanding		 10.04M 10.09M 21.59M 88.25M 83.25M 83.39M 84.26M 81.50M
Weighted Average Basic & Diluted Shares Outstanding		 10.04M 10.09M 21.59M 83.23M 83.34M 84.16M 85.53M 79.67M

Quarterly Income Statements for Atea Pharmaceuticals

This table shows Atea Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -39 -63 -41 -31 -34 -34 -37 -42 -45 -45 -33
Consolidated Net Income / (Loss)		 -39 -63 -41 -31 -34 -34 -37 -42 -45 -45 -33
Net Income / (Loss) Continuing Operations		 -39 -63 -41 -31 -34 -34 -37 -42 -45 -45 -33
Total Pre-Tax Income 		-39 -63 -40 -31 -33 -34 -37 -42 -52 -45 -33
Total Operating Income		 -47 -70 -47 -37 -39 -39 -41 -46 -55 -48 -35
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 47 70 47 37 39 39 41 46 55 48 35
Selling, General & Admin Expense		 12 12 12 11 13 9.46 9.07 7.22 7.12 6.87 6.95
Research & Development Expense		 35 58 35 26 26 30 32 38 48 41 28
Total Other Income / (Expense), net		 7.76 6.87 6.64 6.28 5.71 4.97 4.39 3.71 3.30 2.62 2.19
Interest & Investment Income		 7.76 6.87 6.64 6.28 5.71 4.97 4.39 3.71 3.30 2.62 2.19
Income Tax Expense		 0.35 0.23 0.24 0.23 0.23 0.20 0.21 0.20 -6.77 0.05 0.02
Basic Earnings per Share		 ($0.46) ($0.75) ($0.48) ($0.37) ($0.40) ($0.40) ($0.44) ($0.53) ($0.57) ($0.57) ($0.41)
Weighted Average Basic Shares Outstanding		 83.39M 83.92M 84.25M 84.42M 84.26M 85.16M 83.75M 79.05M 81.50M 79.20M 80.05M
Diluted Earnings per Share		 ($0.46) ($0.75) ($0.48) ($0.37) ($0.40) ($0.40) ($0.44) ($0.53) ($0.57) ($0.57) ($0.41)
Weighted Average Diluted Shares Outstanding		 83.39M 83.92M 84.25M 84.42M 84.26M 85.16M 83.75M 79.05M 81.50M 79.20M 80.05M
Weighted Average Basic & Diluted Shares Outstanding		 84.16M 84.22M 84.42M 84.46M 85.53M 85.58M 79.36M 78.13M 79.67M 80.03M 80.20M

Annual Cash Flow Statements for Atea Pharmaceuticals

This table details how cash moves in and out of Atea Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 20 -13 828 -86 -576 -45 -79 31
Net Cash From Operating Activities		 -7.91 -13 297 -87 -121 -85 -135 -132
Net Cash From Continuing Operating Activities		 -7.91 -13 297 -87 -121 -85 -135 -132
Net Income / (Loss) Continuing Operations		 -9.06 -14 -11 121 -116 -136 -168 -158
Consolidated Net Income / (Loss)		 -9.06 -14 -11 121 -116 -136 -168 -158
Depreciation Expense		 0.02 0.02 0.02 0.03 0.26 0.42 0.42 0.42
Amortization Expense		 - - 0.00 0.00 -5.47 -15 -12 -4.94
Non-Cash Adjustments To Reconcile Net Income		 0.41 0.62 1.64 40 47 49 52 21
Changes in Operating Assets and Liabilities, net		 0.73 0.56 306 -248 -47 16 -7.48 10
Net Cash From Investing Activities		 -0.01 -0.00 -0.03 -0.00 -455 40 56 189
Net Cash From Continuing Investing Activities		 -0.01 -0.00 -0.03 -0.00 -455 40 56 189
Purchase of Property, Plant & Equipment		 -0.01 -0.00 -0.03 -0.00 -1.94 0.00 0.00 0.00
Purchase of Investments		 - - 0.00 0.00 -545 -562 -461 -282
Sale and/or Maturity of Investments		 - - 0.00 0.00 92 603 517 471
Net Cash From Financing Activities		 27 0.00 532 1.47 0.37 0.26 0.27 -26
Net Cash From Continuing Financing Activities		 27 0.00 532 1.47 0.37 0.26 0.27 -26
Repurchase of Common Equity		 - - - - - - 0.00 -26
Issuance of Common Equity		 0.12 0.00 318 0.00 0.14 0.26 0.27 0.20
Other Financing Activities, net		 - - 0.03 1.47 0.23 0.00 0.00 -0.43

Quarterly Cash Flow Statements for Atea Pharmaceuticals

This table details how cash moves in and out of Atea Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 5.94 17 82 -145 -34 55 -32 -10 18 -16 -2.77
Net Cash From Operating Activities		 -22 -40 -42 -23 -30 -31 -33 -40 -28 -46 -37
Net Cash From Continuing Operating Activities		 -22 -40 -42 -23 -30 -31 -33 -40 -28 -46 -37
Net Income / (Loss) Continuing Operations		 -39 -63 -41 -31 -34 -34 -37 -42 -45 -45 -33
Consolidated Net Income / (Loss)		 -39 -63 -41 -31 -34 -34 -37 -42 -45 -45 -33
Depreciation Expense		 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10
Amortization Expense		 -4.35 -3.49 -3.02 -2.60 -2.71 -1.74 -1.32 -1.08 -0.81 -0.58 -0.54
Non-Cash Adjustments To Reconcile Net Income		 12 13 13 12 14 6.95 4.67 4.52 4.40 3.73 3.28
Changes in Operating Assets and Liabilities, net		 9.29 14 -11 -1.64 -8.54 -1.61 0.84 -1.87 13 -4.20 -6.99
Net Cash From Investing Activities		 28 57 125 -122 -3.37 86 15 41 47 30 34
Net Cash From Continuing Investing Activities		 28 57 125 -122 -3.37 86 15 41 47 30 34
Purchase of Investments		 -47 -167 -7.26 -228 -58 -123 -101 -15 -44 -75 -34
Sale and/or Maturity of Investments		 75 224 132 106 55 208 116 56 90 104 68

Annual Balance Sheets for Atea Pharmaceuticals

This table presents Atea Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 22 864 773 667 595 465 315
Total Current Assets		 22 863 772 661 590 462 311
Cash & Equivalents		 22 850 764 188 144 65 96
Short-Term Investments		 - - 0.00 458 434 390 206
Accounts Receivable		 0.00 5.82 - - - - 0.00
Prepaid Expenses		 0.25 7.55 8.03 14 12 7.63 9.16
Plant, Property, & Equipment, net		 0.04 0.05 0.02 1.71 1.29 0.87 0.46
Total Noncurrent Assets		 0.12 0.11 0.47 4.08 3.22 1.44 3.77
Other Noncurrent Operating Assets		 0.12 0.11 0.47 4.08 3.22 1.44 3.77
Total Liabilities & Shareholders' Equity		 22 864 773 667 595 465 315
Total Liabilities		 2.53 316 63 26 40 26 40
Total Current Liabilities		 2.44 316 57 18 32 19 40
Accounts Payable		 0.55 0.06 4.53 2.55 4.25 4.46 13
Accrued Expenses		 1.89 14 52 15 27 13 26
Other Current Liabilities		 - - 0.20 0.72 0.76 0.80 0.84
Total Noncurrent Liabilities		 0.10 0.04 5.93 7.66 7.40 7.20 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -50 548 710 641 555 439 275
Total Preferred & Common Equity		 -50 548 710 641 555 439 275
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -50 548 710 641 555 439 275
Common Stock		 4.64 613 654 701 751 803 798
Retained Earnings		 -54 -65 56 -60 -196 -364 -523
Accumulated Other Comprehensive Income / (Loss)		 - - 0.00 -0.68 0.21 0.23 0.17

Quarterly Balance Sheets for Atea Pharmaceuticals

This table presents Atea Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 608 553 510 491 440 392 343 267 232
Total Current Assets		 603 549 506 487 434 386 336 263 229
Cash & Equivalents		 138 161 243 98 119 88 77 79 77
Short-Term Investments		 457 381 259 384 306 292 252 177 143
Accounts Receivable		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Prepaid Expenses		 8.19 7.27 4.16 4.09 8.27 5.89 6.83 7.19 9.20
Plant, Property, & Equipment, net		 1.39 1.19 1.08 0.98 0.77 0.67 0.56 0.35 0.25
Total Noncurrent Assets		 3.37 3.08 2.93 3.07 5.49 5.34 6.26 3.53 3.37
Other Noncurrent Operating Assets		 3.37 3.08 2.93 3.07 5.49 5.34 6.26 3.53 3.37
Total Liabilities & Shareholders' Equity		 608 553 510 491 440 392 343 267 232
Total Liabilities		 26 49 34 32 29 27 27 33 28
Total Current Liabilities		 19 41 27 25 22 20 20 33 28
Accounts Payable		 0.40 21 5.47 5.79 7.39 8.84 3.52 9.45 10
Accrued Expenses		 18 19 20 19 14 10 16 23 18
Other Current Liabilities		 0.75 0.77 0.78 0.79 0.81 0.82 0.83 0.63 0.42
Total Noncurrent Liabilities		 7.45 7.35 7.30 7.25 7.13 7.07 7.01 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 582 504 476 459 411 364 316 234 204
Total Preferred & Common Equity		 582 504 476 459 411 364 316 234 204
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 582 504 476 459 411 364 316 234 204
Common Stock		 739 764 776 789 809 800 793 802 805
Retained Earnings		 -157 -259 -300 -331 -398 -436 -478 -568 -601
Accumulated Other Comprehensive Income / (Loss)		 -0.26 -0.18 -0.28 0.64 0.12 0.04 0.24 -0.10 -0.10

Annual Metrics And Ratios for Atea Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Atea Pharmaceuticals' official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 82,616,937.00 83,102,730.00 83,287,639.00 83,435,513.00 - 78,126,796.00
DEI Adjusted Shares Outstanding		 0.00 0.00 82,616,937.00 83,102,730.00 83,287,639.00 83,435,513.00 - 78,126,796.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -0.13 1.46 -1.39 -1.63 - -2.03
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 622.49% -100.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -54.24% 24.54% 1,356.98% -198.16% -31.90% -14.04% 9.27%
EBIT Growth		 0.00% -54.14% 24.49% 1,354.55% -194.42% -25.65% -17.54% 6.25%
NOPAT Growth		 0.00% -54.14% 24.49% 1,667.20% -175.58% -25.65% -17.54% 6.25%
Net Income Growth		 0.00% -54.83% 22.00% 1,207.06% -195.64% -17.30% -23.85% 5.96%
EPS Growth		 0.00% -54.44% 63.31% 368.63% -201.46% -17.27% -22.70% 3.00%
Operating Cash Flow Growth		 0.00% -62.23% 2,412.99% -129.32% -39.05% 29.42% -58.67% 2.56%
Free Cash Flow Firm Growth		 0.00% 0.00% 3,707.44% -143.43% -9.92% 29.71% -44.82% 18.33%
Invested Capital Growth		 0.00% 0.00% -14,173.65% 82.04% 88.70% -273.37% 30.81% -66.49%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 69.07% -100.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 265.48% -582.97% -4.68% 4.30% -8.17%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 265.67% -529.33% -4.24% 3.76% -9.64%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 219.76% -403.79% -4.24% 3.76% -9.64%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 390.37% -425.09% -3.61% 3.23% -7.70%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -48.11% -486.11% -3.82% 2.91% -9.60%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 1,253.26% -128.35% 30.81% -0.34% -6.75% 1.62%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 38.31% 0.50% -9.79% 8.06%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 78.97% -243.23% -71.05% 34.74% -95.11%
Profitability Metrics		 - - - - - - - -
Gross Margin		 0.00% 0.00% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% -22.64% 39.39% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% -22.68% 39.38% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% -22.68% 39.38% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% -22.51% 34.49% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 87.45% 97.00% 100.75% 100.55% 96.25%
Interest Burden Percent		 95.64% 96.07% 99.25% 100.15% 91.47% 82.20% 86.79% 90.95%
Effective Tax Rate		 0.00% 0.00% 0.00% 12.56% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -71.81% -3.86% 19.27% -17.16% -22.74% -33.88% -44.34%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% -2.49% 16.91% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% -2.47% 14.81% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 182.15% -3.39% 19.27% -17.16% -22.74% -33.88% -44.34%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 28.31% -2.00% 17.07% -18.09% -24.49% -38.37% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.63 -10 -7.72 121 -91 -115 -135 -127
NOPAT Margin		 0.00% 0.00% -15.88% 34.44% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -35.16% -0.74% 0.02% -3.47% -3.44% -6.45% -8.39%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -20.70% -30.78% -45.97%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 44.50% 13.03% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 78.18% 47.59% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 122.68% 60.62% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -9.48 -15 -11 138 -131 -164 -193 -181
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.46 -15 -11 138 -136 -179 -204 -185
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 6.30 1.05 0.63 0.46 0.64 1.01
Price to Tangible Book Value (P/TBV)		 0.00 0.00 6.30 1.05 0.63 0.46 0.64 1.01
Price to Revenue (P/Rev)		 0.00 0.00 70.98 2.11 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 6.13 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 16.31% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 53.49 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 8.77 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 8.90 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.11 -1.54 -1.28 -1.04 -1.02 -1.04 -1.06
Leverage Ratio		 0.00 1.13 1.56 1.30 1.07 1.06 1.07 1.09
Compound Leverage Factor		 0.00 1.09 1.55 1.30 0.97 0.87 0.93 0.99
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 353.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -253.65% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 66.58 7.23 9.35 9.58 3.59 5.26 1.02
Noncontrolling Interest Sharing Ratio		 0.00% 353.65% 12.18% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 0.00 9.00 2.73 13.58 35.77 18.24 24.85 7.82
Quick Ratio		 0.00 8.90 2.71 13.44 35.00 17.86 24.44 7.59
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -8.11 292 -127 -140 -98 -142 -116
Operating Cash Flow to CapEx		 -65,900.00% -641,450.00% 1,141,284.62% -2,175,125.00% -6,226.56% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.00 0.00 0.11 0.43 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 1,092.88 9,897.66 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 0.00 -2.12 -302 -54 -6.14 -23 -16 -26
Invested Capital Turnover		 0.00 0.00 -0.32 -1.97 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -2.12 -300 248 48 -17 7.06 -11
Enterprise Value (EV)		 0.00 347 2,602 -21 -246 -324 -172 -23
Market Capitalization		 300 300 3,452 743 401 254 283 279
Book Value per Share		 $0.00 ($4.91) $6.63 $8.54 $7.69 $6.65 $5.20 $3.53
Tangible Book Value per Share		 $0.00 ($4.91) $6.63 $8.54 $7.69 $6.65 $5.20 $3.53
Total Capital		 0.00 20 548 710 641 555 439 275
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -22 -850 -764 -647 -578 -455 -302
Capital Expenditures (CapEx)		 0.01 0.00 0.03 0.00 1.94 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -2.19 -302 -49 -4.27 -20 -11 -31
Debt-free Net Working Capital (DFNWC)		 0.00 19 548 716 642 558 444 271
Net Working Capital (NWC)		 0.00 19 548 716 642 558 444 271
Net Nonoperating Expense (NNE)		 2.43 3.81 3.23 -0.19 24 21 33 32
Net Nonoperating Obligations (NNO)		 0.00 -22 -850 -764 -647 -578 -455 -302
Total Depreciation and Amortization (D&A)		 0.02 0.02 0.02 0.03 -5.21 -15 -11 -4.53
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -621.87% -13.90% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 1,126.15% 203.64% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 1,126.15% 203.64% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($0.51) $1.46 ($1.39) ($1.63) ($2.00) ($1.94)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 82.74M 82.82M 83.25M 83.39M 84.26M 81.50M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($0.51) $1.37 ($1.39) ($1.63) ($2.00) ($1.94)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 82.74M 88.25M 83.25M 83.39M 84.26M 81.50M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($0.51) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 21.59M 83.23M 83.34M 84.16M 85.53M 79.67M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.63 -10 -7.72 121 -91 -115 -135 -127
Normalized NOPAT Margin		 0.00% 0.00% -15.88% 34.44% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% -22.51% 39.44% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -16.12%

Quarterly Metrics And Ratios for Atea Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Atea Pharmaceuticals' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 83,435,513.00 83,435,513.00 84,223,100.00 84,422,000.00 - 85,525,179.00 85,579,475.00 79,357,553.00 78,126,796.00 79,672,083.00 80,027,099.00
DEI Adjusted Shares Outstanding		 83,435,513.00 83,435,513.00 84,223,100.00 84,422,000.00 - 85,525,179.00 85,579,475.00 79,357,553.00 78,126,796.00 79,672,083.00 80,027,099.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.47 -0.76 -0.48 -0.37 - -0.40 -0.43 -0.53 -0.57 -0.57 -0.41
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -18.74% -64.28% -28.35% 11.79% 18.06% 44.42% 14.60% -17.24% -33.63% -19.20% 16.51%
EBIT Growth		 -16.73% -67.93% -33.15% 8.79% 16.20% 44.07% 11.87% -22.49% -40.76% -22.97% 15.11%
NOPAT Growth		 -16.73% -67.93% -33.15% 8.79% 16.20% 44.07% 11.87% -22.49% -40.76% -22.97% 15.11%
Net Income Growth		 -13.75% -78.11% -43.78% 6.01% 14.35% 45.75% 8.29% -34.98% -33.76% -32.59% 11.38%
EPS Growth		 -15.00% -74.42% -41.18% 7.50% 13.04% 46.67% 8.33% -43.24% -42.50% -42.50% 6.82%
Operating Cash Flow Growth		 -1.34% -33.55% -161.80% -30.95% -39.22% 23.33% 22.11% -75.28% 7.15% -51.79% -12.82%
Free Cash Flow Firm Growth		 79.20% 73.21% 70.19% 10.60% -117.25% -256.56% -207.48% -181.67% 18.81% 48.78% 37.65%
Invested Capital Growth		 -273.37% -1,509.71% -350.62% -81.34% 30.81% 61.34% 40.58% 44.31% -66.49% -55.36% -0.07%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -12.93% -44.04% 31.91% 20.35% -4.89% 2.30% -4.63% -9.34% -19.55% 12.86% 26.71%
EBIT Q/Q Growth		 -14.19% -49.89% 32.79% 20.71% -4.90% -0.04% -5.90% -10.21% -20.56% 12.61% 26.89%
NOPAT Q/Q Growth		 -14.19% -49.89% 32.79% 20.71% -4.90% -0.04% -5.90% -10.21% -20.56% 12.61% 26.89%
Net Income Q/Q Growth		 -18.17% -61.29% 35.85% 23.13% -7.68% -2.17% -8.43% -13.15% -6.70% -1.28% 27.52%
EPS Q/Q Growth		 -15.00% -63.04% 36.00% 22.92% -8.11% 0.00% -10.00% -20.45% -7.55% 0.00% 28.07%
Operating Cash Flow Q/Q Growth		 -24.12% -82.58% -5.86% 45.42% -31.96% -0.55% -7.55% -22.83% 30.10% -64.37% 20.06%
Free Cash Flow Firm Q/Q Growth		 6.60% 11.21% 8.83% -18.23% -126.99% -45.72% 21.38% -8.31% 34.57% 8.07% 4.29%
Invested Capital Q/Q Growth		 -71.05% -62.00% 30.65% 5.64% 34.74% 9.47% -6.58% 11.56% -95.11% 15.53% 31.35%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.90% 100.37% 100.60% 100.73% 100.68% 100.60% 100.56% 100.47% 86.89% 100.11% 100.07%
Interest Burden Percent		 83.34% 90.16% 85.85% 83.13% 85.37% 87.26% 89.38% 91.85% 93.99% 94.55% 93.76%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -22.74% -29.16% -32.63% -33.45% -33.88% -30.47% -32.38% -37.98% -44.34% -52.58% -58.14%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -22.74% -29.16% -32.63% -33.45% -33.88% -30.47% -32.38% -37.98% -44.34% -52.58% -58.14%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -32.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -33 -49 -33 -26 -27 -27 -29 -32 -38 -34 -25
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.07% -2.46% -1.38% -0.95% -1.21% -1.44% -1.86% -2.50% -1.70% -3.47% -2.79%
Return On Investment Capital (ROIC_SIMPLE)		 -5.87% -9.69% -6.89% -5.68% -6.22% -6.65% -7.94% -10.10% -13.96% -14.38% -12.03%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -47 -70 -47 -37 -39 -39 -41 -46 -55 -48 -35
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -51 -73 -50 -40 -42 -41 -43 -47 -56 -48 -36
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.46 0.67 0.59 0.62 0.64 0.62 0.85 0.73 1.01 1.83 1.82
Price to Tangible Book Value (P/TBV)		 0.46 0.67 0.59 0.62 0.64 0.62 0.85 0.73 1.01 1.83 1.82
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.04 -1.03 -1.04 -1.04 -1.06 -1.05 -1.05 -1.06 -1.06 -1.05
Leverage Ratio		 1.06 1.06 1.05 1.06 1.07 1.08 1.07 1.08 1.09 1.10 1.10
Compound Leverage Factor		 0.88 0.96 0.90 0.88 0.91 0.95 0.96 0.99 1.03 1.04 1.03
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 4.25 4.19 4.94 5.17 6.35 4.88 6.01 3.80 2.34 5.17 4.85
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 18.24 13.28 19.02 19.33 24.85 19.94 19.17 16.66 7.82 7.89 8.13
Quick Ratio		 17.86 13.11 18.87 19.17 24.44 19.56 18.87 16.32 7.59 7.67 7.80
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -16 -14 -13 -15 -34 -50 -39 -43 -28 -26 -25
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -23 -37 -26 -24 -16 -14 -15 -14 -26 -22 -15
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -17 -35 -20 -11 7.06 23 10 11 -11 -7.95 -0.01
Enterprise Value (EV)		 -324 -204 -223 -200 -172 -170 -72 -99 -23 173 153
Market Capitalization		 254 337 279 283 283 256 308 230 279 429 372
Book Value per Share		 $6.65 $6.01 $5.66 $5.43 $5.20 $4.81 $4.26 $3.98 $3.53 $2.93 $2.55
Tangible Book Value per Share		 $6.65 $6.01 $5.66 $5.43 $5.20 $4.81 $4.26 $3.98 $3.53 $2.93 $2.55
Total Capital		 555 504 476 459 439 411 364 316 275 234 204
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -578 -541 -502 -483 -455 -425 -380 -329 -302 -256 -219
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -20 -34 -22 -21 -11 -13 -14 -13 -31 -26 -19
Debt-free Net Working Capital (DFNWC)		 558 507 480 462 444 412 365 316 271 230 201
Net Working Capital (NWC)		 558 507 480 462 444 412 365 316 271 230 201
Net Nonoperating Expense (NNE)		 6.56 14 7.68 5.11 6.22 6.94 8.22 10 6.41 12 8.36
Net Nonoperating Obligations (NNO)		 -578 -541 -502 -483 -455 -425 -380 -329 -302 -256 -219
Total Depreciation and Amortization (D&A)		 -4.24 -3.38 -2.92 -2.49 -2.61 -1.64 -1.22 -0.97 -0.70 -0.48 -0.44
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.46) ($0.75) ($0.48) ($0.37) ($0.40) ($0.40) ($0.44) ($0.53) ($0.57) ($0.57) ($0.41)
Adjusted Weighted Average Basic Shares Outstanding		 83.39M 83.92M 84.25M 84.42M 84.26M 85.16M 83.75M 79.05M 81.50M 79.20M 80.05M
Adjusted Diluted Earnings per Share		 ($0.46) ($0.75) ($0.48) ($0.37) ($0.40) ($0.40) ($0.44) ($0.53) ($0.57) ($0.57) ($0.41)
Adjusted Weighted Average Diluted Shares Outstanding		 83.39M 83.92M 84.25M 84.42M 84.26M 85.16M 83.75M 79.05M 81.50M 79.20M 80.05M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 84.16M 84.22M 84.42M 84.46M 85.53M 85.58M 79.36M 78.13M 79.67M 80.03M 80.20M
Normalized Net Operating Profit after Tax (NOPAT)		 -33 -49 -33 -26 -27 -27 -29 -32 -38 -34 -25
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -16.12% -15.05% -6.91%

Financials Breakdown Chart

Key Financial Trends

Atea Pharmaceuticals remains a development-stage biotechnology company with no reported revenue in the periods provided. Its financial profile is defined by recurring research spending, operating losses and reliance on its cash and investment portfolio to fund operations. The latest quarter showed some improvement in expenses and cash burn, but the company has not yet demonstrated commercial revenue generation.

  • Liquidity remains substantial. As of June 30, 2026, Atea held $76.5 million in cash and equivalents and $142.9 million in short-term investments, for total near-term liquidity of approximately $219.4 million.
  • Debt exposure is limited. Total liabilities were $28.1 million, with no reported noncurrent liabilities. This leaves the company with approximately $204.2 million of shareholders’ equity and reduces near-term interest and refinancing risk.
  • Quarterly operating losses improved. Net loss narrowed to $32.9 million in Q2 2026 from $45.4 million in Q1 2026 and $37.2 million in Q2 2025. The company’s basic loss per share improved to $0.41 from $0.57 in both comparison periods.
  • Operating expenses declined meaningfully. Total operating expenses fell to $35.1 million in Q2 2026 from $48.0 million in Q1 2026 and $41.3 million in Q2 2025. Research and development spending declined to $28.2 million from $41.1 million sequentially, while selling, general and administrative expense also decreased modestly.
  • Cash burn moderated sequentially. Net cash used in operating activities was $37.1 million in Q2 2026, an improvement from $46.4 million in Q1 2026 and $40.4 million in Q3 2025.
  • Share count has decreased from year-ago levels. Weighted-average basic shares outstanding were 80.1 million in Q2 2026, compared with 83.7 million in Q2 2025. This reduction helped limit per-share dilution, although share counts can change as the company funds operations.
  • Investment activity is supporting cash management rather than operating growth. Atea generated $34.3 million of investing cash flow in Q2 2026, primarily from sales and maturities of investments exceeding purchases. These transactions can preserve liquidity, but they do not represent recurring operating cash flow.
  • Investment income provides a partial offset to operating losses. Interest and investment income was $2.2 million in Q2 2026, down from $2.6 million in Q1 2026 and $4.4 million in Q2 2025. The benefit may continue to decline as the investment portfolio becomes smaller.
  • Revenue remains at zero. Atea reported no revenue in each of the income statement periods supplied, leaving the company dependent on cash reserves, investment income and potential future financing or partnerships.
  • Long-term cash depletion remains the central risk. Cash and short-term investments declined from $379.7 million at June 30, 2025, to $219.4 million at June 30, 2026. At the latest quarterly operating burn rate, the combined liquidity balance represents roughly six quarters of funding before considering investment returns, changes in spending or additional financing.

Overall, Atea’s balance sheet remains relatively conservative because liabilities are low and liquid assets substantially exceed obligations. However, total assets and equity have fallen sharply as recurring losses consume capital: total assets declined from $391.6 million in Q2 2025 to $232.3 million in Q2 2026, while retained earnings reached a deficit of $600.9 million. Investors should focus on whether the recent reduction in research spending is sustainable and whether Atea can eventually convert its drug-development programs into revenue before its cash reserves are materially depleted.

10/10/26 01:59 AM ETAI Generated. May Contain Errors.

Atea Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Atea Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Atea Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$158.35 million in 2025, falling from -$9.06 million in 2018. The previous period was -$168.39 million in 2024. Check out Atea Pharmaceuticals' forecast to explore projected trends and price targets.

Atea Pharmaceuticals' total operating income in 2025 was -$180.89 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $180.89 million

Over the last 7 years, Atea Pharmaceuticals' total revenue changed from $0.00 in 2018 to $0.00 in 2025, a change of 0.0%.

In the past 11 quarters, Atea Pharmaceuticals' cash and equivalents has ranged from $76.55 million in Q2 2026 to $243.39 million in Q2 2024, and is currently $76.55 million as of their latest financial filing in Q2 2026.

Atea Pharmaceuticals had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2018.

Over the last 7 years, Atea Pharmaceuticals' book value per share changed from 0.00 in 2018 to 3.53 in 2025, a change of 352.6%.


Related Companies

Financial statements for NASDAQ:AVIR last updated on 8/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
This free guide explains options the way they should be taught
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel
Trump’s issues shocking Executive Order on U.S. Dollar
Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....
Banyan Hill Publishing | Sponsoredtc pixel
A simple options setup that cuts through the noise
Ian Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...
TradeWins | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
The only 5 stocks that matter
SpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...
TradeSmith | Sponsoredtc pixel